Financial Performance - The company achieved a profit attributable to shareholders growth of approximately 8.9% compared to the fiscal year 2024, reflecting prudent strategies and operational rigor[10]. - The company recorded a revenue of approximately HKD 644.4 million for the fiscal year 2025, representing an increase of about 9.1% compared to HKD 590.8 million in fiscal year 2024[19]. - The net profit attributable to the company’s owners for fiscal year 2025 was approximately HKD 26.3 million, an increase of about HKD 2.1 million or 8.9% compared to fiscal year 2024[33]. - The effective tax rate increased from approximately 8.9% in fiscal year 2024 to about 11.1% in fiscal year 2025, due to an increase in taxable income[30]. - The group achieved a profit attributable to shareholders growth of approximately 8.9% year-on-year for the fiscal year 2025[34]. Revenue Growth by Division - Revenue from primary care services increased by approximately HKD 12.4 million or 3.1% to about HKD 410.8 million in fiscal year 2025, driven by an increase in patient visits and average spending per visit[19]. - Revenue from specialist medical services rose by approximately HKD 31.9 million or 23.8% to about HKD 165.8 million in fiscal year 2025, attributed to higher patient visits and average spending[20]. - Revenue from dental services increased by approximately HKD 9.3 million or 15.9% to about HKD 67.8 million in fiscal year 2025, mainly due to increased patient visits following the acquisition of a dental practice[20]. - The primary care division's revenue increased by about 3.1% compared to fiscal year 2024, maintaining stable performance[37]. - The specialty medical division generated revenue of approximately HKD 165.8 million in fiscal year 2025, representing a year-on-year growth of about 23.8%[39]. - The dental division's revenue, including the acquisition of Youde Dental, reached approximately HKD 67.8 million, reflecting a year-on-year increase of about 15.9%[41]. Strategic Initiatives and Expansion - The company plans to expand its primary care network by opening new medical centers and investing in digital platforms to enhance data management and customer engagement[16]. - The group has strategically opened new medical centers in Tsuen Wan, Tsim Sha Tsui, and Causeway Bay to improve accessibility and strengthen its presence in key areas[37]. - The group plans to enhance its specialized medical services, particularly in ophthalmology under the POLYEYE brand, by introducing new surgical techniques and hiring more professionals[66]. - Following the acquisition of Youde Dental, the group aims to strengthen its position in the dental services market and expand its service offerings[66]. - The group continues to maintain partnerships with the Hong Kong government, actively participating in various public health initiatives and community wellness programs[69]. Digital Transformation and Technology Integration - Digital transformation was a core focus, with the implementation of an integrated clinic operation system and a full-service marketing platform across most medical centers[14]. - The group achieved significant progress in digital transformation, implementing a comprehensive clinic operation system and a full-channel marketing platform to enhance customer engagement and satisfaction[46]. - The group integrates technology into operations to enhance care quality and efficiency, reflecting its commitment to improving healthcare services[46]. - The group will implement a comprehensive clinic operation system and a full-access marketing platform across most medical centers in fiscal year 2025, significantly improving clinical workflow coordination and appointment handling[67]. Community Health and Preventive Care - The company maintained close collaboration with the Hong Kong government on community health programs, highlighting its role in supporting healthcare infrastructure[15]. - The company emphasized preventive care and health education, promoting comprehensive health check-up packages through its health management center and online channels[13]. - The group continues to emphasize preventive care through advanced diagnostic health check packages and vaccination services[45]. - The flagship health center, H2, continues to enhance community health awareness through health seminars and workshops[43]. Human Resources and Talent Management - The professional team consists of 431 members, including general practitioners, specialists, and various healthcare professionals, ensuring comprehensive and patient-centered care[62]. - The company emphasizes the importance of attracting and nurturing professional talent to meet the growing patient demand and enhance its cross-departmental collaboration[68]. - The shortage of qualified healthcare professionals is a key issue impacting the healthcare industry, complicating recruitment and retention efforts[186]. - The group's financial performance may be affected if it fails to recruit or retain qualified professionals, as its business model relies on these teams[187]. Corporate Governance and Board Structure - The company has adopted the corporate governance code as its governance framework and has complied with all applicable code provisions for the fiscal year 2025, except for a deviation regarding the separation of the roles of Chairman and CEO[113][114]. - The board consists of six members, including three executive directors and three independent non-executive directors[120]. - The company has established procedures for directors to seek independent advice at reasonable requests, with costs borne by the company[119]. - The company has a policy for directors to retire and seek re-election at least every three years[130]. - The board has mechanisms to address conflicts of interest during decision-making processes[129]. Financial Position and Assets - The group’s net current assets as of June 30, 2025, are approximately HKD 383.9 million, a decrease from HKD 397.8 million as of June 30, 2024[73]. - The group’s interest-bearing bank borrowings as of June 30, 2025, amount to approximately HKD 16.8 million, with a mortgage loan of HKD 8.2 million due in 2036[73]. - The capital debt ratio as of June 30, 2025, is approximately 2.1%, down from 4.0% as of June 30, 2024[74]. - The company’s distributable reserves amounted to approximately HKD 206.7 million, with about HKD 11.4 million recommended for the final dividend[181]. Shareholder Communication and Dividends - The company proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, an increase from HKD 0.028 in fiscal year 2024[176]. - The company maintains effective communication with shareholders through various channels, including interim and annual reports[169]. - The board is committed to ensuring that shareholders can access timely information to exercise their rights and participate in company affairs[168]. - The company has adopted a dividend policy that will be reviewed annually by the board, aiming to provide stable and sustainable returns to shareholders[171]. Industry Challenges and Risks - The group faces strategic risks due to rapidly changing community demands and ongoing global economic uncertainties post-pandemic[186]. - The group emphasizes the importance of maintaining a good reputation in the healthcare sector, as negative news could adversely affect its brand image[188]. - The group has not purchased, sold, or redeemed any of its listed securities in the fiscal year 2025[194].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年10月2日 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 379,552,233 | | | | 379,552,233 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 379,552,233 | | 0 | | 379,552,233 | 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 ...

Human Health Holdings Limited 盈健醫療集團有限公司 （於開曼群島註冊成立的有限公司） 提名委員會 職權範圍 （董事會於2016年1月28日採納 及於 2022年12月15日及 2025年9月25日修訂及採納） 組織 1. 盈健醫療集團有限公司（「公司」）董事（「董事」）會（「董事會」）現議決於董事會 轄下成立一個提名委員會。 出席會議 成員 會議次數 6. 會議次數應不少於每年一次，並應按提名委員會工作所需加開會議。 會議通知 7. 會議通知須於開會前最少三個工作天（或所有提名委員會成員同意的其他較短時間）給予 所有提名委員會成員。 權力 刊登提名委員會職權範圍 12. 提名委員會的職權範圍應刊載於公司網站及「披露易」網站，用以解釋本委員會之角色 及董事會轉授予本委員的權力。 其他事項 2. 提 名 委 員 會 成 員 須 由 董 事 會 委 任 ，其 中 大 部 分 應 為 獨 立 非執行董事（「獨立非執行董 事」）。提名委員會的會議法定人數為兩人。 3. 提名委員會主席（「主席」）須由獨立非執行董事或董事會主席擔任。 4. 提名委員會成員可以親身出席方式或以其他電子通信設備形 ...

Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

盈健医疗(01419)发布公告，该公司将于2026年1月5日派发截至2025年6月30日止年度末期股息每股0.03 港元。 ...

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]

智通财经APP讯，盈健医疗(01419)发布公告，该公司将于2026年1月5日派发截至2025年6月30日止年度 末期股息每股0.03港元。 ...

Human Health Holdings Limited 盈健醫療集團有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號：1419) 陳健平先生，銅紫荊星章，太平紳士 （主席兼行政總裁） 彭麗嫦醫生 （首席醫務總監） 潘振邦先生 （首席營運總監） 獨立非執行董事 呂新榮博士 陳裕光先生 陳希文先生 董事名單及其角色與職能 自 2025 年 10 月 1 日起，盈健醫療集團有限公司董事會（「董事會」）成員載列如下： 執行董事 註 ： C ：有關委員會的主席 M ：有關委員會的成員 香港 董事會轄下設立3個委員會，下表提供各董事會成員在該等委員會中所擔任的職位。 | | 董事會轄下 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 陳健平先生 | | ╱ | M | M | | 彭麗嫦醫生 | | ╱ | ╱ | M | | 呂新榮博士 | | M | C | M | | 陳裕光先生 | | M | M | C | | 陳希文先生 | | C | M | M | 2025年9月25日 ...

EF001 免責聲明 EF001 其他信息 其他信息 不適用 發行人董事 執行董事陳健平先生，銅紫荊星章，太平紳士（亦為行政總裁）、彭麗嫦醫生及潘振邦先生；獨立非執行董事呂新榮 博士、陳裕光先生及陳希文先生。 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 盈健醫療集團有限公司 | | 股份代號 | 01419 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止年度末期股息 | | 公告日期 | 2025年9月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年6月30日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 ...